Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model
OncoImmunology, 2019 Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse +11 more
doaj +1 more source
Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
Frontiers in Pharmacology, 2023 Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated ...
Yosuke Shibata +16 more
doaj +1 more source
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.
Cancer Cell, 2023 Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or functionally attenuated to evoke effective anti-tumor immune responses by ...
Christopher Tay +2 more
semanticscholar +1 more source
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]
, 2018 In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A. +4 more
core +1 more source
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Journal of Hematology & Oncology, 2023 In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies.
Letong Cai +4 more
semanticscholar +1 more source
Expert Opinion on Biological Therapy, 2022 Medical treatment for prostate cancer (PC) targets hormonal pathways used by malignant cells. Research advances aided in gaining knowledge about implicated molecular pathways and opened the way for establishment of new types of therapies by modifying immunological mechanisms.
Mitsogiannis, I. +5 more
openaire +3 more sources
PASD1: a promising target for the immunotherapy of haematological malignancies [PDF]
, 2013 In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in ...
Denniss, Frances +4 more
core +3 more sources
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
British Journal of Cancer, 2020 The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of
H. Raskov +3 more
semanticscholar +1 more source
Emerging phagocytosis checkpoints in cancer immunotherapy
Signal Transduction and Targeted Therapy, 2023 Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as it utilizes patients’ own immune systems in combating the cancer cells.
Yue-Ying Liu +9 more
semanticscholar +1 more source